Sign in
Taking people in United StatesPhase 1/2

Testing semaglutide for weight loss in people with advanced lung disease

Tests whether semaglutide is tolerable in adults with advanced lung disease and obesity.

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Feasibility of Semaglutide in Advanced Lung Disease
Status
Recruiting
Phase
Phase 1/2
People taking part
8 people, planned
Started
29 Jan 2024
Expected to end
28 Dec 2027
Type of study
Interventional
Treatments tested
  • Semaglutide Pen Injector
Record updated
21 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity and advanced lung disease who need extra oxygen when active. It tests whether semaglutide can be taken and tolerated for 12 weeks.

Age
Over 18 and up to 80 years.
Sex
All sexes can join.
Disease stage
Advanced lung disease: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension. Needs extra oxygen on exertion. BMI over 30 kg/m2.
Earlier treatment
Stable treatment for 90 days and use of disease-modifying therapy. No weight loss medication in the last 90 days.

Main reasons for not taking part

  • Diabetes
  • Pregnant or breastfeeding
  • Recent weight loss
  • Recent or chronic stomach and gut problems, or gastroparesis
  • History or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
  • Age > 18
  • BMI > 30 kg/m2
  • Requires supplemental oxygen on exertion
  • Stable treatment regimen X 90 days
  • Use of disease-modifying therapy

Who cannot take part

  • Use of weight loss medication in last 90 days
  • Prior suicide attempt
  • Diabetes
  • History of gastroparesis
  • History of scleroderma
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
  • Uncontrolled thyroid disease
  • History of acute/chronic pancreatitis
  • Pregnant or Breastfeeding
  • Recent weight loss
  • Recent or chronic GI complaints
  • Hospitalized at time of evaluation
  • Suicidal ideation in last 90 days
  • Presence of a pacemaker or defibrillator

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • University of Pennsylvania Perelman School of MedicinePhiladelphia, United StatesContact: Apurva RajeTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.

Read full original descriptionShow less

The main question[s] it aims to answer are:

1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight?

Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

The group in the trial

  • Study Drug (semaglutide)Treatment being tested

    Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy

    Treatment: Semaglutide Pen Injector

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study
Plain-language title
Testing semaglutide for weight loss in people with advanced lung diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05746039, who can take part
Record updated
21 April 2026